

# ~40% of patients with EGFR mut+ NSCLC have a point mutation in exon 21 (L858R)<sup>1</sup>

Historically, patients receiving single-agent EGFR-TKIs with an exon 21 point mutation typically have had lower median PFS benefit than those with exon 19 deletion<sup>2-4</sup>

- In patients with exon 21 mutations, median PFS has **yet to exceed 15 months** with currently available single-agent EGFR-TKIs<sup>3,5</sup>

